# US 2019/0316135 A1 · Novel therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316135 A1
- Document ID: US20190316135A1
- Status: Published application
- Kind: A1
- Application number: 16/341,248
- Filed: 2017-10-13
- Published: 2019-10-17
- Earliest claimed: 2016-10-14
- Assignees: Linnane Pharma AB
- Applicants: Linnane Pharma AB
- Inventors: Catharina SVANBORG; Caterina CAFARO
- Web page: https://patentgrep.com/patent/US20190316135A1

## CPC

- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61P 35/00: Antineoplastic agents
- C07K 14/245: Escherichia (G)
- C12N 1/20: Bacteria; Culture media therefor
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/141: MicroRNAs, miRNAs
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A therapeutic agent comprising a bacteria which expresses an inhibitor of MYC activity or a extract or product obtainable therefrom, for use in for use in the prevention or treatment o disease wherein MYC levels are elevated, such as cancer. Inhibitors of MYC activity comprising a factor obtainable from bacteria are novel and form a further aspect of the invention.

## Claims

### Claim 1

A pharmaceutical composition comprising a bacteria which expresses an inhibitor of MYC activity or a extract or product obtainable therefrom, and at least one pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1 which comprises a bacteria.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1 which comprises a supernatant obtainable by culture of a bacteria.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1 which comprises a factor isolated from a bacteria, which inhibits MYC activity.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1 wherein the bacteria is an attenuated uropathogenic bacteria, or a recombinant bacteria comprising an asymptomatic bacteriuria (ABU) strain which has been engineered to express an inhibitor of MYC activity obtainable from a uropathogenic strain.

### Claim 6 (depends on 5)

The pharmaceutical composition according to claim 5 wherein the attenuated uropathogenic bacteria is an E. coli strain.

### Claim 7 (depends on 6)

The pharmaceutical composition according to claim 6 wherein the bacteria is selected from CFT073 and 536E.

### Claim at position 8

8-9. (canceled)

### Claim 10

A pharmaceutical composition comprising an inhibitor of MYC activity comprising a factor obtainable from a bacteria, and at least one pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

A pharmaceutical composition according to claim 10 wherein the bacteria is a uropathogenic E. coli.

### Claim 12 (depends on 11)

A pharmaceutical composition according to claim 11 wherein the uropathogenic E. coli is selected from CFT073 and 536.

### Claim 13 (depends on 10)

A pharmaceutical composition according to claim 10 wherein the inhibitor of MYC activity comprises a protein or RNA expressed by a gene found in a PAI I or PAI II region of the genome of said bacteria.

### Claim 14 (depends on 13)

A pharmaceutical composition according to claim 13 wherein the gene is a gene found in the PAI I region of the genome.

### Claim 15 (depends on 14)

A pharmaceutical composition according to claim 14 wherein the PAI I region is represented by SEQ ID NO 1.

### Claim 16 (depends on 10)

A pharmaceutical composition according to claim 10 wherein the inhibitor of MYC activity comprises a bacterial ABC transporter protein, a periplasmic binding protein, or an active fragment of either of these.

### Claim 17 (depends on 16)

A pharmaceutical composition according to claim 16 wherein the inhibitor of MYC activity comprises SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4 or an active fragment thereof.

### Claim 18 (depends on 15)

A pharmaceutical composition according to claim 15 wherein the inhibitor of MYC activity is a miRNA molecule.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

A method of treating or preventing a disease in which MYC levels are elevated, said method comprising administering to a patient in need thereof, an effective amount of the pharmaceutical composition according to claim 1.

### Claim 21 (depends on 20)

The method according to claim 20 wherein the disease is cancer.

### Claim 22 (depends on 20)

The method according to claim 20 wherein the cancer is an epithelial or mucosal cancer.

### Claim 23 (depends on 10)

A method of treating or preventing a disease in which MYC levels are elevated, said method comprising administering to a patient in need thereof, an effective amount of the pharmaceutical composition according to claim 10.

### Claim 24 (depends on 23)

The method according to claim 23 wherein the disease is cancer.

### Claim 25 (depends on 23)

The method according to claim 23 wherein the cancer is an epithelial or mucosal cancer.
